KAMES CAPITAL plc Invests $229,000 in Bristol-Myers Squibb Co (BMY) Stock
KAMES CAPITAL plc bought a new position in shares of Bristol-Myers Squibb Co (NYSE:BMY) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,693 shares of the biopharmaceutical company’s stock, valued at approximately $229,000.
Other institutional investors have also bought and sold shares of the company. Sciencast Management LP acquired a new stake in shares of Bristol-Myers Squibb in the first quarter valued at about $602,000. WealthPLAN Partners LLC grew its position in Bristol-Myers Squibb by 240.9% during the first quarter. WealthPLAN Partners LLC now owns 20,040 shares of the biopharmaceutical company’s stock worth $1,268,000 after buying an additional 14,161 shares in the last quarter. Nexthera Capital LP grew its position in Bristol-Myers Squibb by 15.8% during the first quarter. Nexthera Capital LP now owns 342,399 shares of the biopharmaceutical company’s stock worth $21,657,000 after buying an additional 46,799 shares in the last quarter. Garde Capital Inc. acquired a new stake in Bristol-Myers Squibb during the first quarter worth about $305,000. Finally, Private Capital Group LLC grew its position in Bristol-Myers Squibb by 41.0% during the first quarter. Private Capital Group LLC now owns 11,052 shares of the biopharmaceutical company’s stock worth $699,000 after buying an additional 3,214 shares in the last quarter. 72.28% of the stock is currently owned by hedge funds and other institutional investors.
BMY has been the topic of a number of recent research reports. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 target price on the stock in a research report on Friday, October 5th. Guggenheim initiated coverage on Bristol-Myers Squibb in a research report on Monday, October 8th. They set a “neutral” rating on the stock. JPMorgan Chase & Co. lifted their target price on Bristol-Myers Squibb from $70.00 to $74.00 and gave the stock an “overweight” rating in a research report on Monday, October 8th. BMO Capital Markets lifted their target price on Bristol-Myers Squibb from $47.00 to $51.00 and gave the stock a “market perform” rating in a research report on Monday, July 23rd. Finally, SunTrust Banks reissued a “buy” rating and set a $67.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, July 31st. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $62.95.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $0.14. The firm had revenue of $5.70 billion during the quarter, compared to analysts’ expectations of $5.48 billion. Bristol-Myers Squibb had a net margin of 1.74% and a return on equity of 42.58%. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.74 earnings per share. As a group, sell-side analysts anticipate that Bristol-Myers Squibb Co will post 3.62 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, November 1st. Shareholders of record on Friday, October 5th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 2.78%. The ex-dividend date is Thursday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is 53.16%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
See Also: Why Dividend Stocks May Be Right for You
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.